Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 8/20 | 0.77 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.77 |
| ▸ | CDK2 | P24941 | 8/20 | 0.77 |
| ▸ | GSK3B | P49841 | 8/20 | 0.77 |
| ▸ | ATR | Q13535 | 12/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | PRKDC | P78527 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034567 | 0.95 | GSK3B (0.75) | CCNE2CCNE1CDK2GSK3BATR | |
| Hydrochloric Acid SCHEMBL6597556 | 0.94 | GSK3B (0.74) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL6599358 | 0.87 | GSK3B (1.00) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL6035157 | 0.87 | ATR (0.72) | CCNE2CCNE1CDK2GSK3BATR | |
| Hydrochloric Acid SCHEMBL6035742 | 0.86 | GSK3B (0.98) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL6597723 | 0.86 | GSK3B (0.67) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL6034146 | 0.86 | GSK3B (0.84) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL6034278 | 0.86 | GSK3B (0.90) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL6035793 | 0.85 | GSK3B (1.00) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL6034197 | 0.84 | GSK3B (0.70) | CCNE2CCNE1CDK2GSK3BATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| CN-1551869-A | Novel compound | — | 2004-12-01 | — | — | CN | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| CN-1551869-A | Novel compound | — | 2004-12-01 | — | — | CN | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | CCNE2 438/4885CCNE1 386/4885CDK2 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.